Oxa(FA)2

Oxa(FA)2 (trans,cis,cis-[Pt(FA)2(ox)(DACH)]) is a platinum(IV) derivative of oxaliplatin containing two axial ferulate (FA) ligands. Developed by researchers at Leipzig University and Hochschule Merseburg, it is designed as a dual-action hybrid drug that combines the cytotoxic effects of oxaliplatin with the anti-inflammatory properties of ferulic acid. Oxa(FA)2 acts as a prodrug; upon intracellular reduction, it releases active oxaliplatin, which alkylates DNA to inhibit tumor cell replication, and ferulic acid, which targets the inflammatory tumor microenvironment. The compound has demonstrated potent in vitro antiproliferative activity against various breast cancer cell lines, including MCF-7, BT-474, HCC1937, and MDA-MB-468. To optimize delivery and achieve sustained release, Oxa(FA)2 has also been successfully encapsulated within mesoporous silica nanoparticles (SBA-15).

Other names

(trans-R,R-cyclohexane-1,2-diamine)bis(ferulato)(oxalato)platinum(IV)[Oxa(FA)2]oxa(fa)2trans,cis,cis-[Pt(FA)2(ox)(DACH)]trans,cis,cis-[Pt(ferulato)2(oxalato)(1R,2R-diaminocyclohexane)]